Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 22/99 trial was to characterize the specific subset...

Full description

Bibliographic Details
Main Authors: Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Format: Article
Language:English
Published: BMC 2019-09-01
Series:BMC Cancer
Subjects:
HER-positive breast cancer
Trastuzumab monotherapy
Long-term responders
Online Access:http://link.springer.com/article/10.1186/s12885-019-6105-3

Internet

http://link.springer.com/article/10.1186/s12885-019-6105-3

Similar Items